



Histoplasmosis in Israeli Travelers
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Lachish, Neville Berkman, Ami Neuberger and Eli Schwartz
Sheba Medical Center
Histoplasmosis is one of the more common endemic human mycoses.
The majority of infections are acquired in the Americas. We report
23 cases of histoplasmosis in Israeli travelers. All traveled to endemic
areas; 22 to Latin America, one to North America. Fourteen cases
had visited bat habitats, including 9 who visited a specific cave
infested by bats in Lanquin, Guatemala. Fourteen of the 23 patients
were symptomatic; all presented within 3 months of their return
from Latin America. The majority had respiratory symptoms; how-
ever 28% presented with prolonged febrile illness only.
Asymptomatic patients were diagnosed during the evaluation of
incidental radiological findings or because a travel partner had been
suspected of Histoplasma infection. These patients were diagnosed 16-
120 months after their return from the endemic region.
Serological testing was positive in 75% of symptomatic cases but
only 22% of asymptomatic cases.
Histoplasmosis should be considered in travelers returning from
Central or South America with respiratory or febrile illness within
weeks of return, particularly if exposed to bat habitats. Serological
and urinary antigen testing are useful for diagnosis of “early” presen-
ters but wane over time, and thus are of limited utility in late presen-
ters. Evaluation of travel partners may be a useful adjunct in the
returning traveler suspected of having current or healed histoplasmo-
sis. The histoplasmin skin test, if available, may be of use when
attempting to diagnose histoplasmosis in non-endemic areas.
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Workers from feed production often develop allergic respiratory
symptoms and fungi, are likely to be a significant contributing factor
to these symptoms. This study intended to characterize fungal con-
tamination in two feed production units, one for poultry and other
for swine consumption. We aimed at identifying which unit pre-
sented the highest risk of occupational exposure to Aspergillus spp.
Twelve air and twelve surfaces’ samples were collected from the two
studied units through impaction and swabbing methods, respectively.
After laboratory processing and incubation of the collected samples,
quantitative and qualitative results were obtained, with the identifi-
cation of the isolated fungal species. For molecular analysis, 300L of
air were also collected from each same sampling site using the impin-
ger method. Real Time PCR (RT-PCR) was done to perform the
molecular detection of the Aspergillus sections Fumigati and Flavi
(only the toxigenic strains). In the poultry feed production isolates
belonging to the Aspergillus fumigatus species-complex (section Fumi-
gati) were the most abundant in air (46.6%). In the swine feed pro-
duction no isolate from Aspergillus genus was collected. Regarding
the results obtained through molecular methods, A. fumigatus com-
plex was detected in one sampling site in poultry feed production
and in two sampling sites in swine feed production where this spe-
cies-complex was not isolated by conventional methods. Altogether,
the results we obtained with cultural methods showed that feed pro-
duction on poultry was the setting where the highest number of iso-
lates belonging to Aspergillus spp was found. Importantly, the
molecular tools applied during this study enabled to target selected
fungal indicators, allowing a more precise characterization of the
Aspergillus spp. occupational burden in these settings.
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Introduction The pathogenesis of fungal rhinosinusitis/FRS was
widely investigated but the relationship of the fungal presence in
environment and development of FRS is not yet revealed. We evalu-
ated the relationship of the presence of fungi on sinonasal mucosa
with fungal presence in home air of patients with their clinical
characteristics.
Material and methods The prospective study with 136 patients
with chronic rhinosinustis/CRS was conducted in the National Refer-
ence Medical Mycology Laboratory, Faculty of Medicine, University of
Belgrade. Study design included: 1) anamnesis data; 2) measure-
ments of molds specific IgE/sIgE and total IgE Ab, absolute eosino-
phile/Eo count and skin prick test; 3) rhinologic and CT observation;
4) mycological finding of sinonasal nasal aspirate and 5) air sam-
pling from the patient’s bedroom.
Results (i) 30.4% patients with positive molds sIgE Ab had severe
forms of CRS with more often presence of NP (p=0.025); (ii) 46.4%
of patients with positive sIgE Ab had positive fungal finding on nasal
mucosa; (iii) in Serbia the prevalence is 1.3% for allergic FRS/AFRS
and 2.8% for FRS; (iv) patients with AFRS had more frequent asthma
(p=0.024) and CRS lasting more than 10 years (p=0.000); (v) 225
fungus was found in air samples, the most common were A. niger
(57%) and Penicillium sp.(26%).
Conclusion Huge amount of fungal spore in the air of patient’s liv-
ing area should be threat for development of FRS in predisposing
patients. Next studies should clarify the mechanism by which air-
borne fungi turn from ‘normal flora’ into triggers of immunological
reactions, resulting in FRS.
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Production of Echinocandins by Fusarium MS-R1
Segula Masaphy
MIGAL- Galilee Research Institute, Kiryat Shmona, and Tel Hai
College, Upper Galilee, Israel
Fungal infections, especially candidiasis, are on the rise in human
populations, leading to a continuous search for novel potential chem-
icals in order to expand the range of drugs. Filamentous fungi are
important sources of bioactive secondary metabolites, many of which
are used in medicine. This includes production of anti-fungal metabo-
lites that are used to treat human and animal fungal infections.
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Among the antifungal drugs used in medicine, the echinocandins are
considered to be relatively safer than those derived from azole or
polyene compounds. Fusarium strain MS-R1, that produces an anti-
candidal compound was isolated in our laboratory and identified by
molecular means as a member of the Fusarium brachygibbosum com-
plex. The active metabolite was extracted, purified and identified as a
novel echinocandin. It’s activity against range of candida species was
determined, showing activity mainly against Candida albicans and C.
tropicalis. Further studies on the production of the antifungal metabo-
lite by the fungal mycelium were conducted in both solid and liquid
media, with optimization of cultural conditions such as inoculum age
and size and medium manipulations.
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Interactions between bacteria and fungi are well documented in the
literature. To the best of our knowledge no such interactions have
been described regarding the gram negative bacterium Serratia mar-
cescens. An incidental finding in our laboratory found a remarkable
capacity of S. marcescens to migrate along the mycelium of Zygomy-
cete molds. In this work, we conducted a series of experiments to bet-
ter define the nature of this phenomenon. We found that migration
of S. marcescens along fungal mycelium was restricted to Zygomycete
molds, and several Basidiomycete spp. No migration was seen on any
mold of the phylum Ascomycota. S. marcescens migration did not
necessitate fungal viability or surrounding growth medium, as bacte-
ria migrated along aerial hyphae as well. S. marcescens did not exhi-
bit growth tropism towards Zygomycete mycelium. Bacterial
migration along hyphae proceeded only when the hyphae grew into
the bacterial colony. S. marcescens cells initially swarmed along the
hyphae, formed attached microcolonies that grew and coalesced to
generate a biofilm covering the mycelium. Flagellum-defective strains
of S. marcescens were able to migrate along Zygomycete hyphae,
although significantly slower than the wild-type strain. Bacterial
attachment to the mycelium does not necessitate type 1 fimbrial
adhesion since mutants defective in this adhesin migrated equally
well or faster than the wild type strain. Killing does not depend on
the secretion of S. marcescens chitinases as mutants in which all
three chitinase genes were deleted retained wild-type killing abilities.
Better understanding of the mechanisms by which S. marcescens
binds, spreads and kills fungal hyphae could serve as an excellent
model system for such interactions in general; fungal killing could be
employed in agricultural fungal biocontrol.
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Introduction Isavuconazole (ISA) is a new triazole recently
approved for the treatment of invasive aspergillosis. EUCAST has set
the clinical breakpoint of ISA for Aspergillus fumigatus at >1 mg/L (re-
sistant). In this study, we determined the susceptibility of ISA for
489 A. fumigatus isolates and compared the susceptibility to other
mold-active azoles.
Methods Isolates were prospectively collected between June 2014
and December 2015. Minimal inhibitory concentrations (MICs) were
determined by broth microdilution EUCAST method. Isolates were
grouped as azole “wildtype” and “non-wildtype” by the use of epi-
demiological cutoffs for voriconazole, posaconazole and itraconazole
(1 mg/L, 0.25 mg/L and 1 mg/L, respectively). The susceptibility of
ISA was compared to voriconazole, posaconazole and itraconazole for
all isolates as a group and for the defined subgroups by the Spear-
man’s rank correlation coefficient.
Results 279 isolates exhibited a “wildtype” azole phenotype, and
210 were “non-wildtype”. 25/279 “wildtype” isolates had a ISA MIC
of >1 mg/L and were thus classified as resistant. 197/210 of “non-
wildtype” isolates were classified as resistant. The correlation coeffi-
cients for “non-wildtype” isolates were very strong, moderate and
weak (p<0.001) for ISA compared with voriconazole, posaconazole
and itraconazole, respectively. For wildtype isolates the coefficients
were all moderate (p<0.001).
Conclusion Most “azole non-wildtype” isolates were also resistant
for ISA; susceptibility of ISA of non-wildtype isolates had strongest
correlation with voriconazole. Additionally, 25/279 “azole wildtype”
isolates were classified as ISA-resistant. Thus, isolates with “wildtype”
azole susceptibilities, cannot be automatically assumed susceptible for
ISA. Consequently, susceptibility testing of ISA is advised before start-
ing ISA treatment.
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